Utimaco HSM first to be Common Criteria EAL4+-certified according to eIDAS Protection Profile EN 419 221-5
Utimaco, a leading manufacturer of Hardware Security Module (HSM) technology, received the Common Criteria (CC) EAL4+ certification for its CryptoServer CP5 HSM based on the eIDAS Protection Profile EN 419 221-5. CryptoServer CP5 is the first HSM in the market with a CC certification based on this protection profile, making it a future-proof choice for eIDAS trust services. These include local and remote electronic signing and sealing, issuing of certificates, website authentication and timestamping. For application development and regression testing, Utimaco offers a dedicated CryptoServer CP5 HSM simulator to prospects and customers.
eIDAS Protection Profile EN 419 221-5 “Cryptographic Module for Trust Services”
The German hardware security specialist was engaged with and contributed to the creation of the security requirements and protection profiles within the Technical Committee 224, Working Group 17 of the European Committee for Standardization (CEN).
New business opportunities with existing and new partners
For Utimaco business partners, this recent certification opens up a wide range of business opportunities, among which remote signing solutions. German-based IT service provider Bank-Verlag , together with software developer achelos and Utimaco, is developing a Signature Activation Module for banking applications. The service enables bank customers to generate online signatures remotely and speeds up and simplifies processes such as signing contracts, opening an account or issuing insurance policies. Ascertia, a global provider of digital signature creation and verification solutions, will be using the Utimaco CP5 HSM within its ADSS SAM Appliance, a remote QSCD currently undergoing CC EAL4+ certification against EN 419 241-2. There is great market interest in the powerful combination of Ascertia software working with Utimaco HSMs to deliver eIDAS compliant remote signing.
“With eIDAS, the European Commission is looking to stimulate the digital market in Europe,” says Malte Pollmann, CEO of Utimaco. “Being the first vendor certified according to Protection Profile EN 419 221-5, Utimaco helps pave the way for compliant and highly secure trust services. These ambitions are reflected in a number of current and upcoming partner projects.”
Proof of concept with the CryptoServer CP5 simulator
Several companies have already made use of the CryptoServer CP5 simulator for testing purposes in the past months. One of these is Halcom, a provider for digital banking solutions based in Slovenia. Having extensively tested the CP5 HSM’s functionalities with the help of the simulator, Halcom is now able to kick-start the implementation of CryptoServer CP5 into its solution and provide its customers with both secure and compliant trust services.
Luka Ribičič, Head of Halcom-CA, notes: “To be able to offer our clients eIDAS-compliant solutions, cooperating with a trustworthy HSM provider was crucial. The CryptoServer CP5 simulator as well as the affordable price point were key factors in our decision for Utimaco.”
Utimaco is a leading manufacturer of Hardware Security Modules (HSMs) that provide the Root of Trust to many industries, from financial services and payment to the automotive industry, cloud services and the public sector. We keep cryptographic keys and digital identities safe protecting your critical digital infrastructures and high value data assets. Our products enable innovation and support the creation of new business by helping to secure critical business data and transactions.
Founded in 1983, today Utimaco HSMs are deployed across more than 80 countries in more than 1,000 installations. Utimaco employs a total of 200 people, with sales offices in Germany, the US, the UK and Singapore.
For more information, visit https://hsm.utimaco.com/.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an